NT79: A novel neurotensin analog with selective behavioral effects

Brain Research

Volumn 1308, Issue , 2010, Pages 35-46

  Boules, Mona ^a   Liang, Yanqi ^a   Briody, Siobhan ^a   Miura, Tomofumi ^a   Fauq, Irfan ^a   Oliveros, Alfredo ^a   Wilson, Mina ^a   Khaniyev, Shaheen ^a   Williams, Katrina ^a   Li, Zhimin ^a   Qi, Yanfei ^b   Katovich, Michael ^b   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Antinociception; Antipsychotic drugs; Neurotensin analog; Neurotensin receptor; Rat

Indexed keywords

ACETIC ACID; APOMORPHINE; DEXAMPHETAMINE; NEUROTENSIN 79; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; NEUROTENSIN RECEPTOR 2; NEUROTRANSMITTER; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BLOOD PRESSURE; BODY TEMPERATURE; CLIMBING; CONTROLLED STUDY; HOT PLATE TEST; HYPERACTIVITY; IN VIVO STUDY; MICRODIALYSIS; MOLECULAR CLONING; NEUROCHEMISTRY; NOCICEPTION; NONHUMAN; PREDICTION; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; RAT; VISCERAL PAIN; WRITHING TEST;

3,4-DIHYDROXYPHENYLACETIC ACID; ACOUSTIC STIMULATION; ANALGESIA; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; BRAIN; CELLS, CULTURED; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; CRICETULUS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; MICRODIALYSIS; MOTOR ACTIVITY; NEUROTENSIN; PAIN MEASUREMENT; PAIN THRESHOLD; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; SENSORY GATING; SEROTONIN;

ANIMALIA; RATTUS;

EID: 70849110707     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.10.050     Document Type: Article

References (72)

1. Abbott F.V., Hong Y., and Blier P. Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators. Neuropharmacology 35 (1996) 99-110
2. Anden N.E., Rubenson A., Fuxe K., and Hokfelt T. Evidence for dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. 19 (1967) 627-629
3. Auclair A.L., Kleven M.S., Besnard J., Depoortere R., and Newman-Tancredi A. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 31 (2006) 1900-1909
4. Bardin L., Tarayre J.P., Koek W., and Colpaert F.C. In the formalin model of tonic nociceptive pain, 8-OH-DPAT produces 5-HT1A receptor-mediated, behaviorally specific analgesia. Eur. J. Pharmacol. 421 (2001) 109-114
5. Bissette G., Nemeroff C.B., Loosen P.T., Prange A.J., and Lipton M.A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature 262 (1976) 607-609
6. Boules M., Warrington L., Fauq A., McCormick D., and Richelson E. A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity. Eur. J. Pharmacol. 426 (2001) 73-76
7. Boules M., Fredrickson P., and Richelson E. Current topics: brain penetrating neurotensin analog. Life Sci. 73 (2003) 2785-2792
8. Boules M., Fredrickson P., and Richelson E. Neurotensin agonists as an alternative to antipsychotics. Expert Opin. Investig. Drugs 14 (2005) 359-369
9. Boules M., Fredrickson P., and Richelson E. Bioactive analogs of neurotensin. Peptides 27 (2006) 2523-2533
10. Boules M., Shaw A., Fredrickson P., and Richelson E. Neurotensin agonists: potential in the treatment of schizophrenia. CNS Drugs 21 (2007) 13-23
11. Boules M., Shaw A., Liang Y., Barbut D., and Richelson E. NT69L, a novel analgesic, shows synergy with morphine. Brain Res. Brain Res 1294 (2009) 22-28
12. Bredeloux P., Costentin J., and Dubuc I. Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice. Behav. Brain Res. 175 (2006) 399-407
13. Briody, S., Boules, M., Oliveros, A., Fauq, I., Richelson, E., in press. Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance. Behav. Brain Res.
14. Carraway R., and Leeman S.E. Characterization of radioimmunoassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine, and stomach. J. Biol. Chem. 251 (1976) 7045-7052
15. Chalon P., Vita N., Kaghad M., Guillemot M., Bonnin J., Delpech B., Le Fur G., Ferrara P., and Caput D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 386 (1996) 91-94
16. Clineschmidt B.V., McGuffin J.C., and Bunting P.B. Neurotensin: antinocisponsive action in rodents. Eur. J. Pharmacol. 54 (1979) 129-139
17. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D.J., and Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res 856 (2000) 48-54
18. Doak G.J., and Sawynok J. Formalin-induced nociceptive behavior and edema: involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes. Neuroscience 80 (1997) 939-949
19. Dubuc I., Costentin J., Doulut S., Rodriguez M., Martinez J., and Kitabgi P. JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse. Eur. J. Pharmacol. 219 (1992) 327-329
20. Dubuc I., Sarret P., Labbe-Jullie C., Botto J.M., Honore E., Bourdel E., Martinez J., Costentin J., Vincent J.P., Kitabgi P., and Mazella J. Identification of the receptor subtype involved in the analgesic effect of neurotensin. J. Neurosci. 19 (1999) 503-510
21. Ernberg M., Lundeberg T., and Kopp S. Pain and allodynia/hyperalgesia induced by intramuscular injection of serotonin in patients with fibromyalgia and healthy individuals. Pain 85 (2000) 31-39
22. Ervin G.N., Birkemo L.S., Nemeroff C.B., and Prange A.J. Neurotensin blocks certain amphetamine-induced behaviours. Nature 291 (1981) 73-76
23. Fantegrossi W.E., Ko M.C.H., Woods J.H., and Richelson E. Pharmacological effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys. Pharm. Biochem. Behav. 80 (2005) 341-349
24. Fauq A.H., Hong F., Cusack B., Tyler B.M., Pang Y.P., and Richelson E. Synthesis of (2S)-2-amino-3-(1H-4-indolyl) propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides. Tetrahedron: Asymmetry 9 (1998) 4127-4134
25. Feifel D., and Reza T.L. Effects of neurotensin administered into the ventral tegmental area on prepulse inhibition of startle. Behav. Brain Res. 106 (1999) 189-193
26. Feifel D., Minor K.L., Dulawa S., and Swerdlow N.R. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res. 760 (1997) 80-84
27. Ford A.P., and Marsden C.A. In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and D-Trp11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat. Brain Res. 534 (1990) 243-250
28. Gendron L., Perron A., Payet M.D., Gallo-Payet N., Sarret P., and Beaudet A. Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2. Mol. Pharmacol. 66 (2004) 1421-1430
29. Gerhardt S., Gerber R., and Liebman J.M. SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models. Life Sci. 37 (1985) 2355-2363
30. Ghia J.E., Crenner F., Metz-Boutigue M.H., Aunis D., and Angel F. The effect of a chromogranin A-derived peptide (CgA4-16) in the writhing nociceptive response induced by acetic acid in rats. Life Sci. 75 (2004) 1787-1799
31. Giordano J., and Dyche J. Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse. Neuropharmacology 28 (1989) 423-427
32. Giordano J., and Gerstmann H. Patterns of serotonin- and 2-methylserotonin-induced pain may reflect 5-HT3 receptor sensitization. Eur. J. Pharmacol. 483 (2004) 267-269
33. Giordano J., and Rogers L.V. Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats. Eur. J. Pharmacol. 170 (1989) 83-86
34. Goudie A.J., Smith J.A., Robertson A., and Cavanagh C. Clozapine as a drug of dependence. Psychopharmacology (Berl) 142 (1999) 369-374
35. Goudie A.J., Cole J.C., and Sumnall H.R. Olanzapine withdrawal/discontinuation-induced hyperthermia in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 1500-1503
36. Hong Y., and Abbott F.V. Behavioural effects of intraplantar injection of inflammatory mediators in the rat. Neuroscience 63 (1994) 827-836
37. Jolas T., and Aghajanian G.K. Neurotensin and the serotonergic system. Prog. Neurobiol. 52 (1997) 455-468
38. Jolicoeur F.B., De Michele G., Barbeau A., and St-Pierre S. Neurotensin affects hyperactivity but not stereotypy induced by pre and post synaptic dopaminergic stimulation. Neurosci. Biobehav. Rev. 7 (1983) 385-390
39. Jolicoeur, F.B., Gagne, M.A., Rivest, R., Drumheller, A., St-Pierre, S., 1991. Neurotensin selectively antagonizes apomorphine-induced stereotyped climbing. Pharmacol Biochem Behav 38, 463-465.
40. Jolicoeur F.B., Gagne M.A., Rivest R., Drumheller A., and St-Pierre S. Atypical neuroleptic-like behavioral effects of neurotensin. Brain Res. Bull. 32 (1993) 487-491
41. Kalivas P.W., Burgess S.K., Nemeroff C.B., and Prange A.J. Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. Neuroscience 8 (1983) 495-505
42. Kalivas P.W., Nemeroff C.B., and Prange A.J. Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience 11 (1984) 919-930
43. Kitabgi P., Carraway R., and Leeman S.E. Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J. Biol. Chem. 251 (1976) 7053-7058
44. Liang Y., Boules M., Shaw A.M., Williams K., Fredrickson P., and Richelson E. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain. Brain Res. 1231 (2008) 6-15
45. Maeno H., Yamada K., Santo-Yamada Y., Aoki K., Sun Y.J., Sato E., Fukushima T., Ogura H., Araki T., Kamichi S., Kimura I., Yamano M., Maeno-Hikichi Y., Watase K., Aoki S., Kiyama H., Wada E., and Wada K. Comparison of mice deficient in the high- or low-affinity neurotensin receptors, Ntsr1 or Ntsr2, reveals a novel function for Ntsr2 in thermal nociception. Brain Res. 998 (2004) 122-129
46. Mazella J., Botto J.M., Guillemare E., Coppola T., Sarret P., and Vincent J.P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J. Neurosci. 16 (1996) 5613-5620
47. McMahon B.M., Boules M., Warrington L., and Richelson E. Neurotensin analogs indications for use as potential antipsychotic compounds. Life Sci. 70 (2002) 1101-1119
48. Millan M.J. Descending control of pain. Prog. Neurobiol. 66 (2002) 355-474
49. Nemeroff C.B., Luttinger D., Hernandez D.E., Mailman R.B., Mason G.A., Davis S.D., Widerlov E., Frye G.D., Kilts C.A., Beaumont K., Breese G.R., and Prange A.J. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 225 (1983) 337-345
50. Niemegeers C.J., and Janssen P.A. A systematic study of the pharmacological activities of dopamine antagonists. Life Sci. 24 (1979) 2201-2216
51. Okamoto K., Imbe H., Morikawa Y., Itoh M., Sekimoto M., Nemoto K., and Senba E. 5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats. Pain 99 (2002) 133-143
52. Orwin J.M., and Fozard J.R. Blockade of the flare response to intradermal 5-hydroxytryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytryptamine receptors. Eur. J. Clin. Pharmacol. 30 (1986) 209-212
53. Osbahr A.J., Nemeroff C.B., Manberg P.J., and Prange A.J. Centrally administered neurotensin: activity in the Julou-Courvoisier muscle relaxation test in mice. Eur. J. Pharmacol. 54 (1979) 299-302
54. Parada C.A., Tambeli C.H., Cunha F.Q., and Ferreira S.H. The major role of peripheral release of histamine and 5-hydroxytryptamine in formalin-induced nociception. Neuroscience 102 (2001) 937-944
55. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. Third edn. (1997), Academic Press, Inc., San Francisco
56. Pettibone D.J., Hess J.F., Hey P.J., Jacobson M.A., Leviten M., Lis E.V., Mallorga P.J., Pascarella D.M., Snyder M.A., Williams J.B., and Zeng Z. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J. Pharmacol. Exp. Ther. 300 (2002) 305-313
57. Puech A.J., Simon P., and Boissier J.R. Benzamides and classical neuroleptics: comparison of their actions using 6 apomorphine-induced effects. Eur. J. Pharmacol. 50 (1978) 291-300
58. Richardson B.P., Engel G., Donatsch P., and Stadler P.A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316 (1985) 126-131
59. Sarhan S., Hitchcock J.M., Grauffel C.A., and Wettstein J.G. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides 18 (1997) 1223-1227
60. Sarret P., Esdaile M.J., Perron A., Martinez J., Stroh T., and Beaudet A. Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors. J. Neurosci. 25 (2005) 8188-8196
61. Shilling P.D., Richelson E., and Feifel D. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav. Brain Res. 143 (2003) 7-14
62. Shilling P.D., Melendez G., Priebe K., Richelson E., and Feifel D. Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT(2A) and an alpha(1) agonist. Psychopharmacology (Berl) 175 (2004) 353-359
63. Stahle L., and Ungerstedt U. Assessment of dopamine autoreceptor agonist properties of apomorphine, (+)-3-PPP and (-)-3-PPP by recording of yawning behaviour in rats. Eur. J. Pharmacol. 98 (1984) 307-310
64. Sufka K.J., Schomburg F.M., and Giordano J. Receptor mediation of 5-HT-induced inflammation and nociception in rats. Pharmacol. Biochem. Behav. 41 (1992) 53-56
65. Taiwo Y.O., and Levine J.D. Serotonin is a directly-acting hyperalgesic agent in the rat. Neuroscience 48 (1992) 485-490
66. Tambeli C.H., Oliveira M.C., Clemente J.T., Pelegrini-da-Silva A., and Parada C.A. A novel mechanism involved in 5-hydroxytryptamine-induced nociception: the indirect activation of primary afferents. Neuroscience 141 (2006) 1517-1524
67. Tanaka K., Masu M., and Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4 (1990) 847-854
68. Tyler B.M., Cusack B., Douglas C.L., Souder T., and Richelson E. Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception. Brain Res. 792 (1998) 246-252
69. Tyler B.M., Douglas C.L., Fauq A., Pang Y.P., Stewart J.A., Cusack B., McCormick D.J., and Richelson E. In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacology 38 (1999) 1027-1034
70. Tyler-McMahon B.M., Stewart J.A., Farinas F., McCormick D.J., and Richelson E. Highly potent neurotensin analog that causes hypothermia and antinociception. Eur. J. Pharmacol. 390 (2000) 107-111
71. Vita N., Laurent P., Lefort S., Chalon P., Dumont X., Kaghad M., Gully D., Le Fur G., Ferrara P., and Caput D. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett. 317 (1993) 139-142
72. Wheeler-Aceto H., Porreca F., and Cowan A. The rat paw formalin test: comparison of noxious agents. Pain 40 (1990) 229-238